Targeting Signaling Pathways in Solid Tumors, Part C, Volume 389 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as Drugging the Undruggable: Advances in Targeting KRAS Signaling in Solid Tumors, Emerging Trends in Gastrointestinal Cancers: Targeting Developmental Pathways in their Carcinogenesis and Tumor Progression, Importance of targeting various cell signaling pathways in solid cancers, Targeting signaling pathways in cancer stem cells: a potential approach for developing novel anticancer therapeutics, Factors affecting heterogeneity in breast cancer microenvironment: A narrative review, and much more.Additional sections cover Exploring TLR Signaling Pathways as Promising Targets in Cervical Cancer: The Road Less Travelled - Provides the latest information on cancer research - Offers outstanding and original reviews on a range of cancer research topics - Serves as an indispensable reference for researchers and students alike

One of the most exciting areas of cancer research now is the development of agents which can target signal transduction pathways that are activated inappropriately in malignant cells. The understanding of the molecular abnormalities which distinguish malignant cells from their normal counterparts has grown tremendously. This volume summarizes the current research on the role that signal transduction pathways play in the pathogenesis of cancer and how this knowledge may be used to develop the next generation of more effective and less toxic anticancer agents. Series Editor comments: "The biologic behavior of both normal and cancer cells is determined by critical signal transduction pathways. This text provides a comprehensive review of the field. Leading investigators discuss key molecules that may prove to be important diagnostic and/or therapeutic targets."

Targeting Signaling Pathways in Solid Tumors, Part A, Volume 385 in the International Review of Cell and Molecular Biology series, highlights new advances in the field, with this new volume presenting interesting chapters on topics such as Drugging the Undruggable: Advances in Targeting KRAS Signaling in Solid Tumors, Emerging Trends in Gastrointestinal Cancers: Targeting Developmental Pathways in their Carcinogenesis and Tumor Progression, Importance of targeting various cell signaling pathways in solid cancers, Targeting signaling pathways in cancer stem cells: a potential approach for developing novel anticancer therapeutics, Factors affecting heterogeneity in breast cancer microenvironment: A narrative review, and much more.Additional sections cover Exploring TLR Signaling Pathways as Promising Targets in Cervical Cancer: The Road Less Travelled - Provides the latest information on cancer research - Offers outstanding and original reviews on a range of cancer research topics - Serves as an indispensable reference for researchers and students alike

Targetting Signaling Pathways in Solid tumour Part B, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors. - Provides the latest information on cancer research - Offers outstanding and original reviews on a range of cancer research topics - Serves as an indispensable reference for researchers and students alike

This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled "Stem Cells: from Drug to Drug Discovery" which was published in 2017.

This volume examines in detail the role of chronic inflammatory processes in the development of several types of cancer. Leading experts describe the latest results of molecular and cellular research on infection, cancer-related inflammation and tumorigenesis. Further, the clinical significance of these findings in preventing cancer progression and approaches to treating the diseases are discussed. Individual chapters cover cancer of the lung, colon, breast, brain, head and neck, pancreas, prostate, bladder, kidney, liver, cervix and skin as well as gastric cancer, sarcoma, lymphoma, leukemia and multiple myeloma.

Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.